Study on Lipid Profile Changes in Plasma and Intestinal Mucosa of Patients With Inflammatory Bowel Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Inflammatory Bowel Diseases. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Observational Study of Changes in Plasma and Intestinal Mucosa Lipid Profiles in Patients With Inflammatory Bowel Disease
Overview
This study aimed to demonstrate the characteristic lipid profile changes in patients with inflammatory bowel disease.
Detailed description
This study aimed to demonstrate the characteristic lipid profile changes in patients with inflammatory bowel disease.
The investigators followed up with patients with different stages of IBD and collected plasma and lesion tissues from patients and healthy volunteers for lipid metabolism-related substances to assess the changes in lipid metabolism in patients with different stages of IBD and their impact on disease.
Primary outcome measures
- Differential lipid composition between disease and healthy groups [Time frame: 14 weeks]
- Differences in lipid composition between active and remission disease [Time frame: 14 weeks]
Eligibility criteria
Inclusion criteria
- Patients with inflammatory bowel disease; aged 18-80 years; all cases agreed to participate in the study.
- Healthy volunteers who agreed to participate in the study.
Exclusion criteria
- Patients with severe heart disease; patients with severe kidney disease; patients with low blood pressure; patients with severe infections such as sepsis or pneumonia; patients who have used immunosuppressants such as 6-mercaptopurine, imidazole thiopurine, and cyclosporine within a short period, and women during pregnancy; patients who are post-colon resected; patients who disagreed to participate in the study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
China · 1 center
- Carol — Harbin
Identifiers
NCT: NCT06680076 · Harbin Medical University